PRME
Prime Medicine Inc
NASDAQ · Biotechnology
$3.57
+0.33 (+10.19%)
Open$3.36
Previous Close$3.24
Day High$3.59
Day Low$3.30
52W High$6.94
52W Low$1.11
Volume—
Avg Volume3.01M
Market Cap644.42M
P/E Ratio—
EPS$-1.44
SectorBiotechnology
Analyst Ratings
Buy
17 analysts
Price Target
+1,109.8% upside
Current
$3.57
$3.57
Target
$43.19
$43.19
$33.60
$43.19 avg
$71.66
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 4.55M | 5.48M | 82.53M |
| Net Income | -298,131,393 | -323,119,284 | -23,543,617 |
| Profit Margin | -6,566.6% | -6,238.3% | -28.5% |
| EBITDA | -298,763,181 | -341,793,138 | -26,937,435 |
| Free Cash Flow | — | — | -11,662,926 |
| Rev Growth | -17.0% | -17.0% | +18.1% |
| Debt/Equity | — | — | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |